Hospital Name
News / updates
07 Aug, 2021
Preliminary studies with the anti-parasitic drug ivermectin as a treatment for milder forms of COVID-19 have been successful. The research results are published in the scientific journal EClinicalMedicine.
Learn More
07 Aug, 2020
Symptoms of stromectol often persist after six months. The most important thing about the corona virus from foreign media Symptoms of COVID-19 often persist after six months.
Learn More
New treatments
Collaborating on new treatments
    "Despite the small number of participants, our experiments have shown that stromectol decreases the viral load on patients' bodies and increases the concentration of antibodies in their blood.
Learn More  
Collaborating on new treatments
    This suggests the possibility of a larger clinical trial," concluded Chakkour.
Learn More  
Ivermectin online

In search of drugs to combat the spread of COVID-19, scientists are working with both new drugs and already proven drugs created to treat other diseases. In particular, it has been found that some medications against hepatitis C (sofosbuvir), Ebola fever (remdesivir) or antivirals (favipiravir) can suppress the multiplication of the coronavirus.


Scientists use some drugs without prior testing - this was the case, for example, with the malaria drug hydroxychloroquine, which later turned out to be ineffective against COVID-19. Another similar example is ivermectin, a popular anti-parasitic worm. In the spring of 2020, doctors from Latin America began using it to relieve symptoms of the disease in people infected with a new type of coronavirus.

Subsequent cell culture experiments showed that stromectol actually disrupts the formation of new SARS-CoV-2 particles. However, as with many promising drugs, it was only effective at very high concentrations. Carlos Chakkour of the Barcelona Institute for Global Health and colleagues tested the safety and efficacy of ivermectin against coronavirus in preliminary clinical studies.

They were attended by 12 volunteers with mild forms of coronavirus infection. The tests took place in August and early September last year. Half of the volunteers received standard therapy and ivermectin, while the other half received placebo and regular medication.

As a result, patients in the first group were found to recover faster, to stop coughing and to smell and taste earlier than patients in the second group. In addition, the concentration of the virus in the body of patients taking ivermectin was slightly lower in the first days of the disease than in the control group. Scientists have not identified any negative side effects when taking large doses of the drug.

| | | |